• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trial Listings
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Study: Longer data exclusivity for sponsors would increase innovation, extend life expectancy

Study: Longer data exclusivity for sponsors would increase innovation, extend life expectancy

March 3, 2011
CenterWatch Staff

If drugmakers were able to extend their clinical trial data exclusivity to 12 years, it would result in 228 new drugs over the next 50 years and extend the average life expectancy of Americans by 1.7 months.

Those are the assertions of researchers at the University of Southern California’s Leonard D. Schaeffer Center for Health Policy and Economics who recently looked at what it might take to spur more innovation among drug developers. It turns out better profits would. But the down side of long-term innovation is that the cost of new drugs would have to rise in the short term.

John Romley, an economist with the Schaeffer Center and one of the study’s authors, said that makes sense.

“The general economic problem is that we want innovation and all of the benefits that it brings, but with innovation in the pharmaceutical markets, one has to reward, to some degree, the innovator with monopoly power so that the innovator can recoup the enormous cost of developing the drug,” he said. “If drug makers weren’t able to recoup their enormous investments, then they wouldn’t invest in the first place, and wouldn’t that be terrible?”

The report, titled “The Benefits From Giving Makers Of Conventional ‘Small Molecule’ Drugs Longer Exclusivity Over Clinical Trial Data” and published recently in Health Affairs, is the first study to calculate the costs of limiting access to trial data, according to Romley.

Data exclusivity is the period of time before generic drugmakers can use the drug developer’s clinical trial data in manufacturing and marketing generic versions of patented, brand-name drugs. In the U.S., when a pharmaceutical company brings a new drug to the market, it gets five years of exclusive access to the trial data it submitted during the approval process. An added three-year extension is available if new uses for the drug arise, and a six-month extension can be added if the drug is approved for use in pediatric patients.

Extending data exclusivity to 12 years would result in a 5% rise in profits for drug companies, said Romley, which in turn would result in more funds to invest in future innovation, leading to more new drugs and, ultimately, longer life spans.

But is an extra 1.7 months on one’s lifespan worth it? How does one attach a dollar amount to that? The study’s authors point to analysis by Richard Hirth and colleagues of attitudes and behavior related to mortality risk showing that the median value of a life-year ranges from $110,200 to $505,400 (in 2004 U.S. dollars). Further research by Kip Viscusi and Joseph Aldy referenced by the Schaeffer Center researchers indicates that the value of a life-year ranges from $150,000 to $360,000.

Even so, Romley and his colleagues’ assertions present a harsh tradeoff for those currently living with ailments.  “Americans further out in time would benefit, but Americans today would be harmed,” he said.

The authors don’t take a position. “How society makes the tradeoff is not up to us; this is for policymakers to decide,” Romley said. “But one could imagine that politicians might prefer short-term gain.”

So far, no policymakers have reacted to the study, said Romley.

The research was funded by INTERPAT, an association of the chief patent counsels at research-based drugmakers, and by the National Institute on Aging through its support of the Roybal Center for Health Policy Simulation, which is housed at the nonprofit think tank RAND Corp. Three of the study’s authors are principals in Precision Health Economics, a consulting firm that does work for drugmakers.

—Suz Redfearn

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • MAGI East 2023

    MAGI East 2023 Preview: Janssen Reports on Environmental Impact of Trials

  • Complexity-360x240.png

    Phase 3 Trials Significantly Rising in Complexity, Says CSDD

  • Quality Level Scale

    Build Quality into Trials Like You’d Build a House, Says FDA’s BIMO Director

  • DE&I

    Trust-Building, Community Connection Still Essential to DE&I Efforts, Experts Say

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing